Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: concern for immortal time bias effect

Am J Transplant. 2023 Mar;23(3):450. doi: 10.1016/j.ajt.2022.11.021. Epub 2023 Jan 9.

Authors

Julie M Riggs¹, Ananth V Charya², Michael H Eberlein², Robert M Reed², Kapil K Saharia³

Affiliations

¹ Program in Transplantation, University of Maryland Medical Center, Baltimore, Maryland, USA. Electronic address: jriggs@umm.edu.
² Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore, Maryland, USA.
³ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Breakthrough Infections
Humans
Organ Transplantation*
Pre-Exposure Prophylaxis*
Transplant Recipients

Substances

tixagevimab
cilgavimab